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The eﬀect of gender on systemic and brain levels of copper is relatively understudied. We examined gender eﬀects in mice and
human subjects. We observed a trend to higher serum copper levels in female compared to male LaFerla “triple transgenic”
(1399±233 versus 804±436ng/mL, P = 0.06) mice, and signiﬁcantly higher brain copper levels in female- versus male wild-type
mice (5.2 ± 0.2v e r s u s4 .18 ± 0.3ng/mg wet wt, P = 0.03). Plasma copper was signiﬁcantly correlated with brain copper in mice
(R2=0.218; P = 0.038). Among human subjects with AD, both plasma copper (1284±118 versus 853±81ng/mL, P = 0.005) and
cerebrospinal ﬂuid copper (12.8±1v e r s u s1 0 .4±0.7ng/mL,P = 0.01) were elevated in women compared to men. Among healthy
control subjects, plasma copper (1008 ± 51 versus 836 ± 41ng/mL; P = 0.01) was higher in women than in men, but there was
no diﬀerence in cerebrospinal ﬂuid copper. We conclude that gender diﬀerences in copper status may inﬂuence copper-mediated
pathological events in the brain.
1.Introduction
Copper has been implicated in the pathological aggregation
and neurotoxicity of beta amyloid (Aβ)[ 1] in Alzheimer’s
disease (AD). The evidence for “excess” circulating copper in
AD has been reviewed recently [2] and copper-modulating
therapies for AD are being evaluated [3, 4]. Although gender
may inﬂuence the appearance of AD pathology, the eﬀect
of gender on copper status is relatively understudied. Some
publishedreportshavedescribedgenderdiﬀerencesinserum
copper levels [5–7], but the eﬀect of gender upon brain
copper, which is more relevant to AD pathogenesis, has not
been previously described.
Wetestedthehypothesisthatgendermodiﬁesbothcircu-
lating and brain copper levels, with potential consequences
for AD pathology, using samples from an animal model of
AD and from human subjects with and without AD.
2.MaterialsandMethods
2.1. Transgenic Mouse Studies. Breeding pairs of wild-type
and “triple transgenic” (3xTg) mice [8] were generously
provided by Dr. Frank LaFerla, and oﬀspring were raised in
the Portland VA Medical Center Veterinary Medical Unit.
Mice were maintained on AIN93 diet from the time of
weaning, with ad lib deionized water, so dietary intake of
copperwascloselyregulated.Fortheseexperiments,7female
wild type, 7 female transgenic, 4 male wild-type, and 3 male
transgenic mice were used. At the age of 14 months, mice
were euthanized with terminal collection of plasma and with
rapid harvest of brain tissue. Copper levels were determined
in brain (bilateral frontal cortex) and plasma by atomic
absorption spectroscopy. All procedures were approved by
the Portland VA Medical Center Institutional Animal Care
and Use Committee.
2.2. Human Subject Studies. Individuals with AD as well
as healthy control subjects were characterized by clinicians
at the Oregon Health and Science University NIA-funded
Alzheimer’s center. AD was diagnosed according to NINDS-
ADRDA criteria [9]. Healthy control subjects were tested
with neuropsychologic battery and with interview of a
collateral historian to ensure that they are genuinely healthy
controls.2 International Journal of Alzheimer’s Disease
Table 1: Human subject characteristics.
Young control Middle-aged control Old control AD
n 11 16 15 38
Age in years (mean ± SEM) 30 ± 25 0 ± 1.8 74 ± 1.8 70 ± 1.2
Gender (% female) 19% 50% 47% 34%
MMSE 30 ± 1.3 30 ± 1.2 29 ± 1.2 17 ± 0.7
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Figure 1: Serum copper levels (mean ± SEM) in triple transgenic
(tg) and wild-type (wt) mice. Trends to higher serum copper in
females are evident in both strains (P = 0.06 for female tg versus
male tg; P = 0.19 for female wt versus male wt. n = 7f e m a l ew t ,4
male wt, 7 female tg, 3 male tg).
With appropriate Institutional Review Board approvals,
subjects donated plasma by venipuncture and cerebrospinal
ﬂuid by lumber puncture. All lumbar punctures were per-
formed in the AM fasting condition, in the lateral decubitus
position. Both plasma and cerebrospinal ﬂuid were frozen at
−70 until copper measurements were performed by ICPMS.
However, plasma samples from AD patients and controls
were collected in diﬀerent tubes, with AD samples in heparin
tubes and control samples in EDTA tubes (because the
samples were initially collected under diﬀerent protocols
before being deposited in a repository). The use of EDTA
(ratherthenheparinsalt)collectiontubeshasbeenidentiﬁed
as a major source of variability in cross-sectional studies
comparing blood levels across patient populations [2]. The
analysis below consequently does not compare plasma levels
across diagnostic groups.
2.3. Statistical Analysis. Group means were compared by
two-tailed t-test or ANOVA, depending on the number of
means being compared.
3. Results
(1) Serum Copper in Mice. Serum copper is increased (P =
0.06) in female (1399 ± 233ng/mL) compared to male (804
± 436ng/mL) 3xTg mice, and a trend in the same direction
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Figure 2: Brain copper levels (mean ± SEM) in triple transgenic
(tg) and wild-type (wt) mice. Brain copper is signiﬁcantly higher
in female wt compared to male wt mice (P = 0.03), and a trend to
higher brain copper in female tg compared to male tg mice is also
evident (P = 0.15).
is seen in wild-type mice (1467 ± 128ng/mL in females and
1230 ± 169ng/mL in males, P = 0.19) (see Figure 1).
(2) Brain Copper in Mice. Brain copper is signiﬁcantly
increased (P = 0.03) in female (5.2 ± 0.2ng/mg wet wt)
compared to male (4.18 ± 0.3, P = 0.03) wild-type mice,
and a trend in the same direction is seen in 3xTg mice (5.2 ±
0.5 versus 4.2 ± 0.8, P = 0.15; see Figure 2). Plasma copper
was signiﬁcantly correlated with brain copper in mice (R2 =
0.218; P = 0.038).
(3) Human Subject Characteristics. Control subjects were
characterized as “young” (age 20–40, n = 11), middle-aged
(age 41–60, n = 16), and old (age ≥ 60, n = 15). The old
controls did not diﬀer from the AD subjects in mean age
(see Table 1)o ri np e r c e n t a g eo fw o m e n .S u b j e c t sw i t hA D
h a dm i l dd e ﬁ c i t s ,i l l u s t r a t e db ym e a nM M S E= 17 ± 0.7 (see
Table 1).
(4) Plasma Copper in Human Subjects. Plasma copper was
not correlated with age among control subjects or AD
patients. Plasma and cerebrospinal ﬂuid copper were not
correlated in any group.
Plasma copper is increased in human female (1008 ±
51ng/mL) compared to male (836 ± 41) control subjects
(P = 0.01) when all age groups were combined. When theInternational Journal of Alzheimer’s Disease 3
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Figure 3: Plasma copper levels (mean ± SEM) in human AD and
control subjects. Plasma copper is signiﬁcantly increased in female
AD (n = 11) compared to male AD (n = 23) (P = 0.005). There is a
trendtoincreasedplasmacopperinoldfemalecontrolsubjects(n =
6) compared to old male control subjects (n = 8) (P = 0.09) and in
female middle-aged control subjects (n = 8) compared to middle-
aged male control subjects (n = 8) (P = 0.13). When all healthy
control subjects in each gender are combined, there is a signiﬁcant
diﬀerence in plasma copper (P = 0.01, see text).
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Figure 4: Cerebrospinal ﬂuid (CSF) copper levels (mean ± SEM)
in human AD and control subjects. CSF copper is signiﬁcantly
increased in female AD (n = 16) compared to male AD (n = 25)
subjects (P = 0.04), but there are no signiﬁcant diﬀerences in CSF
copper between male and female healthy control subjects.
control subjects were divided by age group, trends to higher
plasma copper in females were appreciated in the middle-
aged and old control subjects, but not the young subjects
(Figure 3).
Among subjects with AD, plasma copper was signiﬁ-
cantly increased in female compared to male AD subjects
(1284 ± 118 versus 853 ± 81ng/mL, P = 0.005).
(5) Cerebrospinal Fluid Copper in Human Subjects. CSF
copper is increased in human female compared to male AD
subjects (12.8 ± 1 versus 10.4 ± 0.7ng/mL, P = 0.01). No
gender-speciﬁc diﬀerence in CSF copper was seen in control
subjects considered as a single group (12.2 ± 0.7 versus 11.6
± 0.52; P = 0.47) or when considered by age group (see
Figure 4). There was also no signiﬁcant diﬀerence between
AD patients and control groups in CSF copper, consistent
with a recent meta-analysis on this topic [2].
4. Discussion
These ﬁndings in both mice and human subjects are
consistent with a small number of publications in human
populations which have found an eﬀect of gender on serum
copper, with higher copper levels in women than in men
[5–7]. The possible confounding eﬀects of dietary intake of
copper [10] or the use of copper-containing supplements
[2] has been emphasized in other studies of human subjects.
However, the demonstration of gender eﬀects in mice, with
strict controls on copper intake which are not possible in
human studies, strengthens the argument that these gender
diﬀerences are due to gender-speciﬁc diﬀerences in copper
traﬃcking rather than diﬀerences in dietary intake.
In some transgenic mice engineered to express AD
pathology, female mice are more prone to AD pathology
t h a nm a l em i c e[ 11], and most studies examining the
eﬀe c to fg e n d e ro nA Dr i s ki nh u m a ns u b j e c t s[ 12–14]
ﬁnd an increased risk in women (although there is some
controversy surrounding this point, with one study ﬁnding
increased risk in women only after age 90 [15]). In light of
these observations, it is interesting to speculate that gender
diﬀerences in copper status, perhaps related in some way to
iron-regulatory mechanisms related to menstruation, might
modulate these apparent gender eﬀects on AD pathology.
Beyond speculation, gender eﬀects on copper may also
be important considerations in the design, conduct, and
analysis of clinical trials of copper-modulating therapy for
AD.
Further investigation of the consequences of gender-
speciﬁc diﬀerences in copper status may be facilitated by
clariﬁcation of the relationship between systemic and central
nervous system copper. The signiﬁcant positive correlation
between serum and brain copper in the mice in this study
supportsthehypothesisthatbloodlevelsarerelevanttobrain
levels of copper, and the concordance between serum and
brain tissue results (with copper levels higher in females in
both cases) provides further support for this view, at least
with respect to frontal cortex.
However, since brain levels are not an option in living
human subjects, these experiments used cerebrospinal ﬂuid
as a surrogate for brain tissue. In the case of subjects
with AD, the eﬀects of gender on plasma and cerebrospinal
ﬂuid copper were concordant, suggesting a blood-brain
relationship similar to that seen in the mice. However,
the absence of a correlation between human plasma and
cerebrospinal ﬂuid copper in both AD and control subjects
suggests that either plasma copper does not reﬂect brain
tissue or that cerebrospinal ﬂuid is not an adequate surrogate
for brain tissue in this instance. Alternatively, it may be4 International Journal of Alzheimer’s Disease
necessary to measure the proportion of CSF copper not
explained by ceruloplasmin in order to appreciate plasma:
CSF correlations, as reported by others [16].
5. Conclusions
These data add to existing evidence that female gender has
an eﬀect on blood levels of copper and provide new evidence
that female gender may also have an eﬀect on brain levels
of copper. Gender eﬀects on copper status may need to be
considered in interpreting experiments, including clinical
trials, which test the hypothesis that copper plays a role in
AD pathogenesis and progression.
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